MedTrace Logo

A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors

NCT04335604 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2022-06-03

No results posted yet for this study

Summary

To assess the Safety, Tolerability, and Pharmacokinetic-pharmacodynamic Profile and efficacy of JPI-547 in patients with advanced solid tumor.

Conditions

Interventions

DRUG

JPI-547

The dose levels will be escalated following a 3+3 dose escalation scheme.

Sponsors & Collaborators

  • Jeil Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Onconic Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-06
Primary Completion
2021-12-14
Completion
2021-12-14

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04335604 on ClinicalTrials.gov